Semaglutide generics may fuel rush for cosmetic weight loss, warn docs

As semaglutide, the blockbuster obesity and diabetes drug, goes off-patent in India, clearing the way for a wave of lower-cost generics, doctors across the country are reporting a sharp rise in patient inquiries.

- ANJALI SINGH & SANKET KOUL Mumbai/New Delhi, 20 March

These are coming not only from people with diabetes or chronic obesity, but also from otherwise healthy individuals seeking weight loss.

Clinicians say the expected price drop has significantly broadened interest in the therapy, a trend further amplified by social media buzz and influencer-led promotion.

“There are clear clinical criteria for prescribing this drug, and it is not meant for cosmetic weight loss,” said Rajiv Kovil, a senior Mumbai-based diabetologist. He noted that patients without diabetes must meet defined body mass index thresholds and also have obesity-related conditions to qualify. He added that treating it as a “weight-loss shortcut” would trivialise its wider role as a disease-modifying therapy with benefits for cardiovascular, liver and metabolic health.